Geron (GERN) Change in Accured Expenses (2010 - 2026)
Geron (GERN) posted Change in Accured Expenses of -$21.0 million for Q1 2026, down 232.1% sequentially from $15.9 million in Q4 2025, and down 59.11% YoY from -$51.4 million in Q1 2025.
Geron (GERN) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Geron has reported Change in Accured Expenses for 17 years, with the latest figure at -$21.0 million in Q1 2026.
- Quarterly Change in Accured Expenses fell 59.11% year-over-year to -$21.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.0 million (up 196.91% YoY) and the FY2025 annual result came in at $15.8 million, up 431.79% from the prior year.
- Change in Accured Expenses slipped to -$21.0 million in Q1 2026 per GERN's latest filing, from $15.9 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $28.0 million in Q3 2022 and troughed at -$21.0 million in Q1 2026.
- A 5-year average of $29176.5 and a median of -$3.9 million in 2023 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses jumped 1980.45% in 2022, then slumped 1340.64% in 2023.
- Over 5 years, Change in Accured Expenses stood at -$20.6 million in 2022, then surged by 81.2% to -$3.9 million in 2023, then sank by 142.67% to -$9.4 million in 2024, then surged by 269.08% to $15.9 million in 2025, then sank by 232.1% to -$21.0 million in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$21.0 million, $15.9 million, and $21.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | -382,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -382,000.00 |
| Jun 30, 2026 | -382,000.00 |
| Mar 31, 2026 | -21.01 Mn |
| Mar 31, 2026 | -21.01 Mn |
| Dec 31, 2025 | 15.90 Mn |
| Dec 31, 2025 | 15.90 Mn |
| Sep 30, 2025 | 21.37 Mn |
| Sep 30, 2025 | 21.37 Mn |
| Jun 30, 2025 | -8.28 Mn |
| Jun 30, 2025 | -8.28 Mn |
| Mar 31, 2025 | -13.20 Mn |
| Mar 31, 2025 | -13.20 Mn |
| Dec 31, 2024 | -9.41 Mn |
| Dec 31, 2024 | -9.41 Mn |
| Sep 30, 2024 | 9.56 Mn |
| Sep 30, 2024 | 9.56 Mn |
| Jun 30, 2024 | 4.81 Mn |
| Jun 30, 2024 | 4.81 Mn |
| Mar 31, 2024 | -9.72 Mn |
| Mar 31, 2024 | -9.72 Mn |